Roche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduction from hours-long infusions. It offers a less burdensome option for thousands of patients. The medicine, subcutaneous Tecentriq, is now approved for non-small cell lung cancer. This innovation aims to ease the strain on overcrowded cancer centers across India.